Developing Transformative Cell and Exosome-based Therapeutics

Capricor Therapeutics is a biotechnology company offering a new approach on drug development in Duchenne muscular dystrophy and beyond. We are patient-focused first, while advancing precision medicine.

Learn More About Us View Our Corporate Deck

Optimizing Patient-focused Medicine

We offer a multi-stage pipeline exploring allogeneic cardiosphere-derived cells (CDCs) and exosome science for novel therapeutic approaches to treat a broad range of serious diseases.

View Our Pipeline

Accelerating the Development of Precision Science

Capricor’s science is focused on cell and exosome-based biology, offering multiple modalities allowing us to create a new class of therapeutic medicines for patients.

Explore Our Science

Latest News

Jun 24, 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Jun 20, 2025

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Jun 17, 2025

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

View All